Clinical Evaluation of Dicumarinyl Derivatives with a Metabolic Study of the Radioactively Labeled Anticoagulants in Animals

Authors:
  • EHEric P. Hausner
    Eric P. Hausner
  • CSCharles L. Shafer
    Charles L. Shafer
  • MCMarion Corson
    Marion Corson
  • OJOgden Johnson
    Ogden Johnson
  • TTTheodore Trujillo
    Theodore Trujillo
  • WLWright Langham
    Wright Langham

Abstract
The common use of dicumarinyl derivatives for the treatment of thromboembolic diseases justifies further clinical evaluation of dicumarol and 4,4'-dihydroxydicumarinyl ethyl acetate [Pelentan, Tromexan, 3,3'-carboxymethylenebis (4-hydroxycoumarin) ethyl ester.] The need for a more thorough understanding of the pharmacodynamic action of dicumarinyl anticoagulants has prompted a study of their gross metabolism in animals, using C 14 -labeled materials.

This publication has 3 references indexed in Scilit: